Federated Hermes Inc. Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Federated Hermes Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 47.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 249,591 shares of the biopharmaceutical company's stock after acquiring an additional 80,668 shares during the period. Federated Hermes Inc. owned about 0.19% of Alnylam Pharmaceuticals worth $58,731,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Himension Capital Singapore PTE. LTD. acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $1,066,000. Envestnet Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 110.5% during the fourth quarter. Envestnet Asset Management Inc. now owns 66,014 shares of the biopharmaceutical company's stock worth $15,534,000 after buying an additional 34,647 shares in the last quarter. Aviva PLC lifted its stake in shares of Alnylam Pharmaceuticals by 215.2% in the 4th quarter. Aviva PLC now owns 77,244 shares of the biopharmaceutical company's stock valued at $18,176,000 after acquiring an additional 52,738 shares during the last quarter. Resona Asset Management Co. Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $8,637,000. Finally, Prudential PLC grew its position in Alnylam Pharmaceuticals by 41.9% during the 4th quarter. Prudential PLC now owns 4,280 shares of the biopharmaceutical company's stock worth $1,007,000 after acquiring an additional 1,264 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at $20,802,989.42. This represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Up 5.1 %

Shares of ALNY stock traded up $11.49 on Friday, hitting $237.77. The stock had a trading volume of 1,577,336 shares, compared to its average volume of 863,403. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business has a 50 day moving average of $253.20 and a 200 day moving average of $258.37. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The stock has a market cap of $30.93 billion, a price-to-earnings ratio of -109.57 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a "buy" rating and a $353.00 price target on the stock. Chardan Capital reiterated a "buy" rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Scotiabank lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a report on Monday, March 31st. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $315.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.